Չարորակ նեյրոլեպտիկ համախտանիշ (Armenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Չարորակ նեյրոլեպտիկ համախտանիշ" in Armenian language version.

refsWebsite

Global rank Armenian rank

35nih.gov

4^th place

3^rd place

25doi.org

2^nd place

4^th place

8archive.org

6^th place

5web.archive.org

1^st place

2psu.edu

207^th place

1,078^th place

1rarediseases.org

5,181^st place

1,583^rd place

1nashuatelegraph.com

low place

1ulb.ac.be

low place

1google.com

163^rd place

169^th place

1uptodate.com

3,771^st place

983^rd place

1semanticscholar.org

11^th place

428^th place

1jfponline.com

low place

1cmaj.ca

low place

3,750^th place

1idiom.com

low place

archive.org

Strawn JR, Keck PE, Caroff SN (2007). «Neuroleptic malignant syndrome». The American Journal of Psychiatry. 164 (6): 870–6. doi:10.1176/ajp.2007.164.6.870. PMID 17541044.
Buckley PF, Hutchinson M (1995). «Neuroleptic malignant syndrome». Journal of Neurology, Neurosurgery, and Psychiatry. 58 (3): 271–3. doi:10.1136/jnnp.58.3.271. PMC 1073359. PMID 7897404.
Steinberg, Martin; Lyketsos, Constantine G. (2012 թ․ սեպտեմբեր). «Atypical Antipsychotic Use in Patients With Dementia: Managing Safety Concerns». The American Journal of Psychiatry. 169 (9): 900–906. doi:10.1176/appi.ajp.2012.12030342. PMC 3516138. PMID 22952071.
Gurrera RJ (1999). «Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome». The American Journal of Psychiatry. 156 (2): 169–80. doi:10.1176/ajp.156.2.169 (inactive 2019 թ․ դեկտեմբերի 11). PMID 9989551.{{cite journal}}: CS1 սպաս․ DOI inactive as of 2019 (link)
Mendhekar DN, Duggal HS (2006). «Persistent amnesia as a sequel of olanzapine-induced neuroleptic malignant syndrome». The Journal of Neuropsychiatry and Clinical Neurosciences. 18 (4): 552–3. doi:10.1176/jnp.2006.18.4.552. PMID 17135384.
Pelonero AL, Levenson JL, Pandurangi AK (1998). «Neuroleptic malignant syndrome: a review». Psychiatric Services. 49 (9): 1163–72. doi:10.1176/ps.49.9.1163. PMID 9735957.
Hernández JL, Palacios-Araus L, Echevarría S, Herrán A, Campo JF, Riancho JA (1997). «Neuroleptic malignant syndrome in the acquired immunodeficiency syndrome». Postgraduate Medical Journal. 73 (866): 779–84. doi:10.1136/pgmj.73.866.779. PMC 2431511. PMID 9497946.
Hasan S, Buckley P (1998). «Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique». The American Journal of Psychiatry. 155 (8): 1113–6. doi:10.1176/ajp.155.8.1113. PMID 9699705.

cmaj.ca

Birmes P, Coppin D, Schmitt L, Lauque D (2003). «Serotonin syndrome: a brief review». CMAJ. 168 (11): 1439–42. PMC 155963. PMID 12771076.

doi.org

Berman, BD (2011 թ․ հունվար). «Neuroleptic malignant syndrome: a review for neurohospitalists». The Neurohospitalist. 1 (1): 41–7. doi:10.1177/1941875210386491. PMC 3726098. PMID 23983836.
Strawn JR, Keck PE, Caroff SN (2007). «Neuroleptic malignant syndrome». The American Journal of Psychiatry. 164 (6): 870–6. doi:10.1176/ajp.2007.164.6.870. PMID 17541044.
Khaldi S, Kornreich C, Choubani Z, Gourevitch R (2008). «Antipsychotiques atypiques et syndrome malin des neuroleptiques : brève revue de la littérature» [Neuroleptic malignant syndrome and atypical antipsychotics: A brief review] (PDF). L'Encéphale (French). 34 (6): 618–24. doi:10.1016/j.encep.2007.11.007. PMID 19081460.{{cite journal}}: CS1 սպաս․ չճանաչված լեզու (link)
Keyser DL, Rodnitzky RL (1991). «Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy». Archives of Internal Medicine. 151 (4): 794–6. doi:10.1001/archinte.151.4.794. PMID 1672810.
Friedman LS, Weinrauch LA, D'Elia JA (1987). «Metoclopramide-induced neuroleptic malignant syndrome». Archives of Internal Medicine. 147 (8): 1495–7. doi:10.1001/archinte.147.8.1495. PMID 3632154.
Buckley PF, Hutchinson M (1995). «Neuroleptic malignant syndrome». Journal of Neurology, Neurosurgery, and Psychiatry. 58 (3): 271–3. doi:10.1136/jnnp.58.3.271. PMC 1073359. PMID 7897404.
Keck PE, Pope HG, Cohen BM, McElroy SL, Nierenberg AA (1989). «Risk factors for neuroleptic malignant syndrome. A case-control study». Archives of General Psychiatry. 46 (10): 914–8. doi:10.1001/archpsyc.1989.01810100056011. PMID 2572206.
Otani K, Horiuchi M, Kondo T, Kaneko S, Fukushima Y (1991). «Is the predisposition to neuroleptic malignant syndrome genetically transmitted?». The British Journal of Psychiatry. 158 (6): 850–3. doi:10.1192/bjp.158.6.850. PMID 1678666.
Alexander PJ, Thomas RM, Das A (1998). «Is risk of neuroleptic malignant syndrome increased in the postpartum period?». The Journal of Clinical Psychiatry. 59 (5): 254–5. doi:10.4088/JCP.v59n0509a. PMID 9632037.
Steinberg, Martin; Lyketsos, Constantine G. (2012 թ․ սեպտեմբեր). «Atypical Antipsychotic Use in Patients With Dementia: Managing Safety Concerns». The American Journal of Psychiatry. 169 (9): 900–906. doi:10.1176/appi.ajp.2012.12030342. PMC 3516138. PMID 22952071.
Mihara K, Kondo T, Suzuki A, Yasui-Furukori N, Ono S, Sano A, Koshiro K, Otani K, Kaneko S (2003). «Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome». American Journal of Medical Genetics Part B. 117B (1): 57–60. doi:10.1002/ajmg.b.10025. PMID 12555236.
Kornhuber J, Weller M, Riederer P (1993). «Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis». Journal of Neural Transmission. Parkinson's Disease and Dementia Section. 6 (1): 63–72. doi:10.1007/bf02252624. PMID 8105799.
Chatterjee A (2014). «Glutamate-based magnetic resonance spectroscopy in neuroleptic malignant syndrome». Annals of Indian Academy of Neurology. 17 (1): 123–4. doi:10.4103/0972-2327.128579. PMC 3992752. PMID 24753679.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Odagaki Y (2009). «Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics?». Current Drug Safety. 4 (1): 84–93. CiteSeerX 10.1.1.334.241. doi:10.2174/157488609787354387. PMID 19149529.
Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T (2004). «Neuroleptic malignant syndrome and atypical antipsychotic drugs». The Journal of Clinical Psychiatry. 65 (4): 464–70. doi:10.4088/JCP.v65n0403. PMID 15119907.
Gurrera RJ (1999). «Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome». The American Journal of Psychiatry. 156 (2): 169–80. doi:10.1176/ajp.156.2.169 (inactive 2019 թ․ դեկտեմբերի 11). PMID 9989551.{{cite journal}}: CS1 սպաս․ DOI inactive as of 2019 (link)
Northoff G (2002). «Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology». Journal of Neural Transmission. 109 (12): 1453–67. CiteSeerX 10.1.1.464.9266. doi:10.1007/s00702-002-0762-z. PMID 12486486.
Sachdev PS (2005). «A rating scale for neuroleptic malignant syndrome». Psychiatry Research. 135 (3): 249–56. doi:10.1016/j.psychres.2005.05.003. PMID 15996751.
Ahuja, N.; Cole, A. J. (2009). «Hyperthermia syndromes in psychiatry». Advances in Psychiatric Treatment. 15 (3): 181–91. doi:10.1192/apt.bp.107.005090.
Mendhekar DN, Duggal HS (2006). «Persistent amnesia as a sequel of olanzapine-induced neuroleptic malignant syndrome». The Journal of Neuropsychiatry and Clinical Neurosciences. 18 (4): 552–3. doi:10.1176/jnp.2006.18.4.552. PMID 17135384.
Pelonero AL, Levenson JL, Pandurangi AK (1998). «Neuroleptic malignant syndrome: a review». Psychiatric Services. 49 (9): 1163–72. doi:10.1176/ps.49.9.1163. PMID 9735957.
Hernández JL, Palacios-Araus L, Echevarría S, Herrán A, Campo JF, Riancho JA (1997). «Neuroleptic malignant syndrome in the acquired immunodeficiency syndrome». Postgraduate Medical Journal. 73 (866): 779–84. doi:10.1136/pgmj.73.866.779. PMC 2431511. PMID 9497946.
Velamoor VR (1998). «Neuroleptic malignant syndrome. Recognition, prevention and management». Drug Safety. 19 (1): 73–82. doi:10.2165/00002018-199819010-00006. PMID 9673859.
Gurrera RJ (2002). «Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia?». Clinical Neuropharmacology. 25 (4): 183–93. doi:10.1097/00002826-200207000-00001. PMID 12151905.
Hasan S, Buckley P (1998). «Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique». The American Journal of Psychiatry. 155 (8): 1113–6. doi:10.1176/ajp.155.8.1113. PMID 9699705.

google.com

Aronson, Jeffrey K. (2015). Meyler's Side Effects of Drugs: The International Encyclopedia of Adverse Drug Reactions and Interactions (անգլերեն). Elsevier. էջ 607. ISBN 978-0-444-53716-4.

idiom.com

Friedberg JM. Neuroleptic malignant syndrome. URL: «Archived copy». Արխիվացված է օրիգինալից 2006 թ․ հոկտեմբերի 16-ին. Վերցված է 2006 թ․ հուլիսի 3-ին.{{cite web}}: CS1 սպաս․ արխիվը պատճենվել է որպես վերնագիր (link). Accessed: July 3, 2006.Կաղապար:Self-published inline

jfponline.com

Latham J, Campbell D, Nichols W, Mott T (2008). «How much can exercise raise creatine kinase level—and does it matter?». The Journal of Family Practice. 57 (8): 545–7. PMID 18687233. Արխիվացված օրիգինալից 2016 թ․ հունիսի 1-ին.

nashuatelegraph.com

Stacy Milbouer, "Quest for the truth", Nashua Telegraph http://www.nashuatelegraph.com/apps/pbcs.dll/article?AID=/20050424/NEWS01/104240081 Արխիվացված 2007-09-27 Wayback Machine

nih.gov

pubmed.ncbi.nlm.nih.gov

Berman, BD (2011 թ․ հունվար). «Neuroleptic malignant syndrome: a review for neurohospitalists». The Neurohospitalist. 1 (1): 41–7. doi:10.1177/1941875210386491. PMC 3726098. PMID 23983836.
Strawn JR, Keck PE, Caroff SN (2007). «Neuroleptic malignant syndrome». The American Journal of Psychiatry. 164 (6): 870–6. doi:10.1176/ajp.2007.164.6.870. PMID 17541044.
Khaldi S, Kornreich C, Choubani Z, Gourevitch R (2008). «Antipsychotiques atypiques et syndrome malin des neuroleptiques : brève revue de la littérature» [Neuroleptic malignant syndrome and atypical antipsychotics: A brief review] (PDF). L'Encéphale (French). 34 (6): 618–24. doi:10.1016/j.encep.2007.11.007. PMID 19081460.{{cite journal}}: CS1 սպաս․ չճանաչված լեզու (link)
Keyser DL, Rodnitzky RL (1991). «Neuroleptic malignant syndrome in Parkinson's disease after withdrawal or alteration of dopaminergic therapy». Archives of Internal Medicine. 151 (4): 794–6. doi:10.1001/archinte.151.4.794. PMID 1672810.
Friedman LS, Weinrauch LA, D'Elia JA (1987). «Metoclopramide-induced neuroleptic malignant syndrome». Archives of Internal Medicine. 147 (8): 1495–7. doi:10.1001/archinte.147.8.1495. PMID 3632154.
Buckley PF, Hutchinson M (1995). «Neuroleptic malignant syndrome». Journal of Neurology, Neurosurgery, and Psychiatry. 58 (3): 271–3. doi:10.1136/jnnp.58.3.271. PMC 1073359. PMID 7897404.
Keck PE, Pope HG, Cohen BM, McElroy SL, Nierenberg AA (1989). «Risk factors for neuroleptic malignant syndrome. A case-control study». Archives of General Psychiatry. 46 (10): 914–8. doi:10.1001/archpsyc.1989.01810100056011. PMID 2572206.
Otani K, Horiuchi M, Kondo T, Kaneko S, Fukushima Y (1991). «Is the predisposition to neuroleptic malignant syndrome genetically transmitted?». The British Journal of Psychiatry. 158 (6): 850–3. doi:10.1192/bjp.158.6.850. PMID 1678666.
Alexander PJ, Thomas RM, Das A (1998). «Is risk of neuroleptic malignant syndrome increased in the postpartum period?». The Journal of Clinical Psychiatry. 59 (5): 254–5. doi:10.4088/JCP.v59n0509a. PMID 9632037.
Steinberg, Martin; Lyketsos, Constantine G. (2012 թ․ սեպտեմբեր). «Atypical Antipsychotic Use in Patients With Dementia: Managing Safety Concerns». The American Journal of Psychiatry. 169 (9): 900–906. doi:10.1176/appi.ajp.2012.12030342. PMC 3516138. PMID 22952071.
Mihara K, Kondo T, Suzuki A, Yasui-Furukori N, Ono S, Sano A, Koshiro K, Otani K, Kaneko S (2003). «Relationship between functional dopamine D2 and D3 receptors gene polymorphisms and neuroleptic malignant syndrome». American Journal of Medical Genetics Part B. 117B (1): 57–60. doi:10.1002/ajmg.b.10025. PMID 12555236.
Kornhuber J, Weller M, Riederer P (1993). «Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis». Journal of Neural Transmission. Parkinson's Disease and Dementia Section. 6 (1): 63–72. doi:10.1007/bf02252624. PMID 8105799.
Chatterjee A (2014). «Glutamate-based magnetic resonance spectroscopy in neuroleptic malignant syndrome». Annals of Indian Academy of Neurology. 17 (1): 123–4. doi:10.4103/0972-2327.128579. PMC 3992752. PMID 24753679.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Odagaki Y (2009). «Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics?». Current Drug Safety. 4 (1): 84–93. CiteSeerX 10.1.1.334.241. doi:10.2174/157488609787354387. PMID 19149529.
Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T (2004). «Neuroleptic malignant syndrome and atypical antipsychotic drugs». The Journal of Clinical Psychiatry. 65 (4): 464–70. doi:10.4088/JCP.v65n0403. PMID 15119907.
Gurrera RJ (1999). «Sympathoadrenal hyperactivity and the etiology of neuroleptic malignant syndrome». The American Journal of Psychiatry. 156 (2): 169–80. doi:10.1176/ajp.156.2.169 (inactive 2019 թ․ դեկտեմբերի 11). PMID 9989551.{{cite journal}}: CS1 սպաս․ DOI inactive as of 2019 (link)
Northoff G (2002). «Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology». Journal of Neural Transmission. 109 (12): 1453–67. CiteSeerX 10.1.1.464.9266. doi:10.1007/s00702-002-0762-z. PMID 12486486.
Latham J, Campbell D, Nichols W, Mott T (2008). «How much can exercise raise creatine kinase level—and does it matter?». The Journal of Family Practice. 57 (8): 545–7. PMID 18687233. Արխիվացված օրիգինալից 2016 թ․ հունիսի 1-ին.
Sachdev PS (2005). «A rating scale for neuroleptic malignant syndrome». Psychiatry Research. 135 (3): 249–56. doi:10.1016/j.psychres.2005.05.003. PMID 15996751.
Christensen V, Glenthøj B (2001). «[Malignant neuroleptic syndrome or serotonergic syndrome]». Ugeskrift for Lægerer. 163 (3): 301–2. PMID 11219110.
Birmes P, Coppin D, Schmitt L, Lauque D (2003). «Serotonin syndrome: a brief review». CMAJ. 168 (11): 1439–42. PMC 155963. PMID 12771076.
Dhib-Jalbut S, Hesselbrock R, Mouradian MM, Means ED (1987). «Bromocriptine treatment of neuroleptic malignant syndrome». The Journal of Clinical Psychiatry. 48 (2): 69–73. PMID 3804991.
Mendhekar DN, Duggal HS (2006). «Persistent amnesia as a sequel of olanzapine-induced neuroleptic malignant syndrome». The Journal of Neuropsychiatry and Clinical Neurosciences. 18 (4): 552–3. doi:10.1176/jnp.2006.18.4.552. PMID 17135384.
Pelonero AL, Levenson JL, Pandurangi AK (1998). «Neuroleptic malignant syndrome: a review». Psychiatric Services. 49 (9): 1163–72. doi:10.1176/ps.49.9.1163. PMID 9735957.
Hernández JL, Palacios-Araus L, Echevarría S, Herrán A, Campo JF, Riancho JA (1997). «Neuroleptic malignant syndrome in the acquired immunodeficiency syndrome». Postgraduate Medical Journal. 73 (866): 779–84. doi:10.1136/pgmj.73.866.779. PMC 2431511. PMID 9497946.
Velamoor VR (1998). «Neuroleptic malignant syndrome. Recognition, prevention and management». Drug Safety. 19 (1): 73–82. doi:10.2165/00002018-199819010-00006. PMID 9673859.
Gurrera RJ (2002). «Is neuroleptic malignant syndrome a neurogenic form of malignant hyperthermia?». Clinical Neuropharmacology. 25 (4): 183–93. doi:10.1097/00002826-200207000-00001. PMID 12151905.
Hasan S, Buckley P (1998). «Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique». The American Journal of Psychiatry. 155 (8): 1113–6. doi:10.1176/ajp.155.8.1113. PMID 9699705.

ncbi.nlm.nih.gov

Berman, BD (2011 թ․ հունվար). «Neuroleptic malignant syndrome: a review for neurohospitalists». The Neurohospitalist. 1 (1): 41–7. doi:10.1177/1941875210386491. PMC 3726098. PMID 23983836.
Buckley PF, Hutchinson M (1995). «Neuroleptic malignant syndrome». Journal of Neurology, Neurosurgery, and Psychiatry. 58 (3): 271–3. doi:10.1136/jnnp.58.3.271. PMC 1073359. PMID 7897404.
Steinberg, Martin; Lyketsos, Constantine G. (2012 թ․ սեպտեմբեր). «Atypical Antipsychotic Use in Patients With Dementia: Managing Safety Concerns». The American Journal of Psychiatry. 169 (9): 900–906. doi:10.1176/appi.ajp.2012.12030342. PMC 3516138. PMID 22952071.
Chatterjee A (2014). «Glutamate-based magnetic resonance spectroscopy in neuroleptic malignant syndrome». Annals of Indian Academy of Neurology. 17 (1): 123–4. doi:10.4103/0972-2327.128579. PMC 3992752. PMID 24753679.{{cite journal}}: CS1 սպաս․ չպիտակված ազատ DOI (link)
Birmes P, Coppin D, Schmitt L, Lauque D (2003). «Serotonin syndrome: a brief review». CMAJ. 168 (11): 1439–42. PMC 155963. PMID 12771076.
Hernández JL, Palacios-Araus L, Echevarría S, Herrán A, Campo JF, Riancho JA (1997). «Neuroleptic malignant syndrome in the acquired immunodeficiency syndrome». Postgraduate Medical Journal. 73 (866): 779–84. doi:10.1136/pgmj.73.866.779. PMC 2431511. PMID 9497946.

ninds.nih.gov

«Neuroleptic Malignant Syndrome Information Page | National Institute of Neurological Disorders and Stroke». www.ninds.nih.gov. Արխիվացված օրիգինալից 2017 թ․ հուլիսի 4-ին. Վերցված է 2017 թ․ հուլիսի 1-ին.

psu.edu

citeseerx.ist.psu.edu

Odagaki Y (2009). «Atypical neuroleptic malignant syndrome or serotonin toxicity associated with atypical antipsychotics?». Current Drug Safety. 4 (1): 84–93. CiteSeerX 10.1.1.334.241. doi:10.2174/157488609787354387. PMID 19149529.
Northoff G (2002). «Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology». Journal of Neural Transmission. 109 (12): 1453–67. CiteSeerX 10.1.1.464.9266. doi:10.1007/s00702-002-0762-z. PMID 12486486.

rarediseases.org

«Neuroleptic Malignant Syndrome - NORD (National Organization for Rare Disorders)». NORD (National Organization for Rare Disorders). 2004. Արխիվացված օրիգինալից 2017 թ․ փետրվարի 19-ին. Վերցված է 2017 թ․ հուլիսի 1-ին.

semanticscholar.org

Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T (2004). «Neuroleptic malignant syndrome and atypical antipsychotic drugs». The Journal of Clinical Psychiatry. 65 (4): 464–70. doi:10.4088/JCP.v65n0403. PMID 15119907.

ulb.ac.be

dipot.ulb.ac.be

Khaldi S, Kornreich C, Choubani Z, Gourevitch R (2008). «Antipsychotiques atypiques et syndrome malin des neuroleptiques : brève revue de la littérature» [Neuroleptic malignant syndrome and atypical antipsychotics: A brief review] (PDF). L'Encéphale (French). 34 (6): 618–24. doi:10.1016/j.encep.2007.11.007. PMID 19081460.{{cite journal}}: CS1 սպաս․ չճանաչված լեզու (link)

uptodate.com

«UpToDate». www.uptodate.com.

web.archive.org

«Neuroleptic Malignant Syndrome - NORD (National Organization for Rare Disorders)». NORD (National Organization for Rare Disorders). 2004. Արխիվացված օրիգինալից 2017 թ․ փետրվարի 19-ին. Վերցված է 2017 թ․ հուլիսի 1-ին.
«Neuroleptic Malignant Syndrome Information Page | National Institute of Neurological Disorders and Stroke». www.ninds.nih.gov. Արխիվացված օրիգինալից 2017 թ․ հուլիսի 4-ին. Վերցված է 2017 թ․ հուլիսի 1-ին.
Stacy Milbouer, "Quest for the truth", Nashua Telegraph http://www.nashuatelegraph.com/apps/pbcs.dll/article?AID=/20050424/NEWS01/104240081 Արխիվացված 2007-09-27 Wayback Machine
Latham J, Campbell D, Nichols W, Mott T (2008). «How much can exercise raise creatine kinase level—and does it matter?». The Journal of Family Practice. 57 (8): 545–7. PMID 18687233. Արխիվացված օրիգինալից 2016 թ․ հունիսի 1-ին.
Friedberg JM. Neuroleptic malignant syndrome. URL: «Archived copy». Արխիվացված է օրիգինալից 2006 թ․ հոկտեմբերի 16-ին. Վերցված է 2006 թ․ հուլիսի 3-ին.{{cite web}}: CS1 սպաս․ արխիվը պատճենվել է որպես վերնագիր (link). Accessed: July 3, 2006.Կաղապար:Self-published inline